OverviewSuggest Edit

Eisai is a research-based human health care company which discovers, develops, packages, and markets pharmaceutical products with focus on neurology, oncology, Alzheimer's disease, epilepsy, and metabolic disorders. It offers a portfolio of tablets and injections for treatment of various diseases. The Company‘s areas of research and development focus include neuroscience, oncology, vascular, inflammatory and immunological reaction, and antibody-based programs.

TypePublic
Founded1941
HQBunkyo City, JP
Websiteus.eisai.com

Latest Updates

Employees (est.) (Mar 2021)11,237(+3%)
Job Openings120
Revenue (FY, 2021)¥645.9 B(-7%)
Share Price (May 2022)$43.7(+5%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Eisai

Haruo Naito

Haruo Naito

Chief Executive Officer
Tatsuyuki Yasuno

Tatsuyuki Yasuno

President, Eisai Inc. and the Americas Region
Lynn D. Kramer

Lynn D. Kramer

Chief Clinical Officer, Neurology Business Group
Stephen Davies

Stephen Davies

Vice President, Eisai Strategic Information Systems
Alexander Scott

Alexander Scott

Executive Vice President, Integrity
Takashi Owa

Takashi Owa

Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group
Show more

Eisai Office Locations

Eisai has offices in Bunkyo City, Atsugi, Baltimore, Cambridge and in 24 other locations
Bunkyo City, JP (HQ)
4 Chome-6-10 Koishikawa
Atsugi, JP
Iiyama
Wien, AT
Leonard-Bernstein-Straße 10
Leuven, BE
Brusselsestraat 190/bus 4
Mississauga, CA
6925 Century Ave #701
Benxi Shi, CN
Pingtai 2nd St, Xihu Qu
Show all (37)

Eisai Financials and Metrics

Eisai Revenue

Eisai's revenue was reported to be ¥645.94 b in FY, 2021
JPY

Revenue (Q3, 2022)

203.0b

Gross profit (Q3, 2022)

170.7b

Net income (Q3, 2022)

13.0b

EBITDA (Q3, 2022)

25.2b

EBIT (Q3, 2022)

13.6b

Market capitalization (13-May-2022)

12.5b

Closing stock price (13-May-2022)

43.7

Cash (31-Dec-2021)

258.4b

EV

(156.0b)
Eisai's current market capitalization is $12.5 b.
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

600.1b642.8b695.6b645.9b

Cost of goods sold

(175.1b)(162.1b)(149.7b)(133.8b)

Gross profit

425.0b480.8b547.4b513.6b

R&D expense

(139.6b)(144.8b)(140.1b)(150.3b)
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

153.3b156.8b157.1b154.0b145.3b186.8b165.6b151.5b181.3b198.9b163.5b203.0b

Cost of goods sold

(41.2b)(37.2b)(43.3b)(34.6b)(34.9b)(32.6b)(29.6b)(32.4b)(31.3b)(29.8b)(32.4b)(32.7b)

Gross profit

112.1b119.7b113.8b124.2b111.0b155.3b136.7b118.9b150.2b182.5b131.3b170.7b

R&D expense

(34.1b)(30.9b)(36.5b)(29.4b)(38.6b)(35.0b)(30.5b)(37.0b)(40.6b)(41.8b)(38.1b)(43.4b)
Annual
JPYFY, 2017FY, 2018FY, 2019FY, 2020

Cash

214.0b204.7b221.7b207.0b

Accounts Receivable

142.9b137.3b170.1b147.4b

Inventories

80.9b67.9b65.7b85.1b
Quarterly
JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

279.7b291.8b248.6b225.5b215.4b212.5b226.3b228.0b193.8b213.1b283.0b258.4b

Accounts Receivable

148.8b149.3b165.9b168.6b164.1b196.7b184.0b183.0b202.0b236.3b174.6b214.6b

Inventories

70.4b71.0b66.1b63.9b65.1b66.4b70.9b74.9b78.9b89.9b90.0b92.5b
Annual
JPYFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

76.8b89.5b128.1b

Depreciation and Amortization

26.2b26.8b33.7b
Quarterly
JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

21.3b49.7b59.5b27.0b33.8b75.8b32.4b34.4b58.4b55.8b61.3b75.2b

Depreciation and Amortization

6.9b13.7b20.1b8.3b16.5b25.1b8.7b17.7b26.8b9.5b19.3b29.2b
Show all financial metrics

Eisai Operating Metrics

Jul, 2018Jul, 2019

Phase I Trials Products

1514

Phase II Trials Products

1315

Phase I/II Trials Products

66

Phase III Trials Products

1114
Show all operating metrics

Eisai Acquisitions / Subsidiaries

Company NameDateDeal Size
AkaRxJanuary 07, 2010$255 m
MorphotekMarch 22, 2007$325 m
EA Pharma Co., Ltd.
Eisai AB
Eisai Asia Regional Services Pte. Ltd.
Eisai Australia Pty. Ltd.
Eisai B.V.
Eisai China Holdings Ltd.
Eisai China Inc.
Eisai Clinical Research Singapore Pte. Ltd.
Show more

Eisai Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Eisai Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Eisai Online and Social Media Presence

Embed Graph

Eisai News and Updates

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway

STOCKHOLM, May 9, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval...

Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease

Research collaboration will test novel algorithm's effectiveness on Geisinger data DANVILLE, Pa. and NUTLEY, N.J., April 4, 2022 /PRNewswire/ -- Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in...

Humira Market Size by 2021-2027 | Trends, Revenue and Share | Top Players Analysis - AbbVie, Eisai, Cadila Healthcare

Humira market size was USD 17920 million and it is expected to reach USD 10150 million by the end of 2027. Humira market size was USD 17920 million and it is expected to reach USD 10150 million by the end of 2027.

Dow Jones Newswires: Eisai shares sink after Japan regulators seek more data for review of Alzheimer’s drug

Eisai Co. shares fell as much as 9.2% early Thursday morning after a Japanese government panel sought additional data for a review of the company's Aduhelm drug for Alzheimer's.

Eisai Presents Final Results Of Phase IV Elevate Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) At The American Epilepsy Society (AES) 2021 Annual Meeting

WOODCLIFF LAKE, N.J., Dec. 7, 2021 /PRNewswire/ -- Eisai Inc. presented analyses of the ELEVATE study of its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2021 American Epilepsy Society (AES) Annual Meeting. ELEVATE was a multicenter, open-label, Phase IV study of FYCOMPA as...

Worldwide Migraine Drugs Industry to 2026 - Featuring Allergan, Amgen and Eisai Among Others

Dublin, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The "Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global migraine drugs market exhibited strong growth during 2015-2020. Migraine is …
Show more

Eisai Frequently Asked Questions

  • When was Eisai founded?

    Eisai was founded in 1941.

  • Who are Eisai key executives?

    Eisai's key executives are Haruo Naito, Tatsuyuki Yasuno and Lynn D. Kramer.

  • How many employees does Eisai have?

    Eisai has 11,237 employees.

  • What is Eisai revenue?

    Latest Eisai annual revenue is ¥645.9 b.

  • What is Eisai revenue per employee?

    Latest Eisai revenue per employee is ¥57.5 m.

  • Who are Eisai competitors?

    Competitors of Eisai include Nipro Corporation, Allegheny Health Network and Hemato Oncologos.

  • Where is Eisai headquarters?

    Eisai headquarters is located at 4 Chome-6-10 Koishikawa, Bunkyo City.

  • Where are Eisai offices?

    Eisai has offices in Bunkyo City, Atsugi, Baltimore, Cambridge and in 24 other locations.

  • How many offices does Eisai have?

    Eisai has 37 offices.